Frequency and costs of ischemic and bleeding complications after percutaneous coronary interventions: Rationale for new antithrombotic agents

Journal of Invasive Cardiology

Volumn 14, Issue SUPPL. B, 2002, Pages

  Moscucci, Mauro ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; CLOPIDOGREL; EPTIFIBATIDE; HEPARIN; PYRIDINE DERIVATIVE; TICLOPIDINE; TIROFIBAN;

ANTICOAGULATION; BLEEDING; CARDIOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DRUG RESEARCH; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HUMAN; INTERVENTIONAL RADIOLOGY; REIMBURSEMENT; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGE FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD TRANSFUSION; CLINICAL TRIALS; CORONARY ARTERY BYPASS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FIBRINOLYTIC AGENTS; HEALTH CARE COSTS; HUMANS; ISCHEMIA; POSTOPERATIVE HEMORRHAGE; TREATMENT OUTCOME; UNITED STATES;

EID: 0036225776     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization and coronary angioplasty in 70 catheterization laboratories
2. The impact of statistical adjustment on economic profiles of interventional cardiologists
3. Mathematical modeling in the assessment of quality improvement and cost reduction efforts in percutaneous coronary interventions
4. In-hospital cost of percutaneous coronary revascularization. Critical determinants and implications
5. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty
6. Reuse of balloon catheters for coronary angioplasty: A potential cost-saving strategy?
7. Safety and cost effectiveness of combined coronary angiography and angioplasty
8. Reducing costs and improving outcomes of percutaneous transluminal coronary interventions
9. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
10. Predictors of length of stay after coronary stenting
11. Percutaneous coronary interventions in the United States: Changing practice patterns and outcomes
12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
13. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
14. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
15. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty
16. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina. The CAPTURE study
17. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
18. Hemorrhagic complications in association with percutaneous coronary intervention: Can the risk be attenuated?
19. Novel dosing of eptifibatide in planned coronary stent implantation (ESPRIT): A randomized, placebo-controlled trial
20. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
21. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction
22. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
23. Do tirofiban and ReoPro give similar efficacy?
24. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
25. The effects of contemporary use of coronary stents on in-hospital mortality
26. The relationship between operator volume and outcomes after percutaneous interventions in high volume hospitals in 1994-96: The Northern New England Experience
27. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting
28. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: Results in 7,472 octogenarians
29. Predictors of length of stay after coronary stenting
30. Outcomes and costs of ischemic complications and bleeding in patients undergoing percutaneous coronary interventions
31. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions
32. Cause of in-hospital death in 12,232 consecutive patients undergoing percutaneous transluminal coronary angioplasty
33. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
34. Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions
35. Comparative 30-day economic and clinical outcomes of platelet gtycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie Reo-Pro Versus Integrilin Cost Evaluation (PRICE) Trial
36. Blood transfusion after percutaneous coronary interventions: A potential target for quality improvement
37. Vascular complications after balloon and new device angioplasty
38. Peripheral vascular complications of directional coronary atherectomy and stenting: Predictors, management, and outcome
39. Acute and long-term cost implications of coronary stenting
40. Fundamentals of economic analysis
41. Economic impact on physicians and hospitals of proposed changes in Medicare reimbursement for coronary interventions
42. Economic impact of GP IIb/IIIa blockade after high-risk angioplasty. Results from the RESTORE trial
43. Clinical correlates of the initial and long-term cost of coronary bypass surgery and coronary angioplasty
44. Economic assessment ofplatelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization. Results from the EPILOG Randomized Trial
45. Coronary artery stent outcomes in a Medicare population: Less emergency bypass surgery and lower mortality rates in patients with stents
46. Acute and long-term cost implications of coronary stenting
47. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1)
48. Cost-effectiveness of coronary stenting in acute myocardial infarction: Results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial
49. ACC clinical competence statement: Recommendations for the assessment and maintenance of proficiency in coronary interventional procedures
50. Accreditation of hospitals for percutaneous coronary intervention on the basis of volume or clinical outcome using MEDPAR data sets: Effect on patient mortality, cost and treatment accessibility
51. Cost analysis of bivalirudin in percutaneous coronary intervention